Sprint Bioscience (Q2 review): Continued positive progress - Redeye
Redeye returns with an update after Sprint Bioscience's Q2 report, which was in line with our expectations. We slightly raise our fundamental DCF value and introduce our composite fair value.
ANNONS
Redeye returns with an update after Sprint Bioscience's Q2 report, which was in line with our expectations. We slightly raise our fundamental DCF value and introduce our composite fair value.
